Hoth Therapeutics reports positive HT-VA CRADA data

Hoth Therapeutics (HOTH) “announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement with the U.S. Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease.”